Loading patent…
AssigneeImmatics Biotechnologies GmbH
InventorsColette SONG, Heiko SCHUSTER, Daniel Johannes KOWALEWSKI, Oliver SCHOOR, Jens FRITSCHE, Toni WEINSCHENK, Harpreet SINGH
Estimating the term…
The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules
A method of treating a patient who has cancer, comprising administering to said patient a population of activated T cells that kill cancer cells that present a peptide consisting of the amino acid sequence of TELEVKIRDW (SEQ ID NO:
A method of treating a patient who has breast cancer, gallbladder cancer, head and neck squamous cell carcinoma, non-small cell lung adenocarcinoma, lung squamous cell carcinoma, esophageal cancer, pancreatic cancer, or urinary bladder carcinoma, comprising administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, wherein said peptide consists of the amino acid sequence of TELEVKIRDW (SEQ ID NO:
Dependencies are inferred from the claim text.